Advancing Hope: AFTD Holds 2023 Holloway Summit Meeting on Biomarkers for FTD
The second annual AFTD Holloway Summit, focused on biomarkers for FTD, was held from November 30 to December 1 in Miami Beach, FL. More than 50 attendees from academia, industry,…
Read MoreDear HelpLine: Dealing With Genetic Uncertainty
Dear HelpLine, Each time I visit home for the holidays and see firsthand how FTD has affected my parent, my anxiety increases. Is it normal to worry that other family…
Read MoreAFTD and ADDF Extend Treat FTD Fund Program Through 2035
AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have committed to extending the Treat FTD Fund program through 2035, providing an additional ten years of support to accelerate treatment development…
Read MoreGene Therapy for FTD: What Do I Need to Know?
In the last several years, new clinical trials have begun for drugs that can potentially slow or stop the progression of FTD caused by specific genes. Gene therapy and gene…
Read MoreThe Lived Experience of FTD: Grief on the FTD Journey
The following article was written by members of AFTD’s Persons with FTD Advisory Council, who work to ensure that the insights and voices of people living with FTD help guide…
Read MorePassage Bio Announces Hopeful Initial Data from Phase 1/2 Clinical Trial
Passage Bio released promising preliminary results from its phase 1/2 clinical trial evaluating an experimental treatment for FTD cases caused by a GRN genetic mutation (FTD-GRN). The “upliFT-D” trial is…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)